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Background/Aims: There is a need for new anti-asthmatic medications with fewer side effects. NDC-052, an extract of 
the medicinal herb Magnoliae flos, which has a long history of clinical use, was recently found to have anti-inflammatory 
effects. Herein, we evaluated the effects of NDC-052 as an add-on therapy in patients with mild to moderate asthma using 
inhaled corticosteroids (ICS).
Methods: In a non-comparative, multi-center trial, 148 patients taking ICS received NDC-052 for eight weeks. We 
evaluated their forced expiratory volume in one second (FEV1), morning and evening peak expiratory flow rate (AM and 
PM PEFR), AM/PM asthma symptom scores, visual analogue symptom (VAS) scores, night-time wakening, frequency of 
short-acting β2-agonist usage, and adverse events.
Results: After eight weeks, both AM and PM PEFRs were significantly improved. Asthma symptom scores, VAS scores, 
the frequency of nights without awakening, and the frequency of β2-agonist use were also reduced. Most of the adverse 
drug reactions were mild and resolved spontaneously.
Conclusions: The addition of NDC-052
 to ICS had a beneficial effect on asthma control in patients with mild to moderate 
asthma, with good tolerability and fewer side effects. Further studies are necessary to evaluate the effects of NDC-052 in 
patients with severe and/or refractory asthma. 
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IntRoduCtIon
Asthma is a common chronic inflammatory disease of 
the airways that is responsible for significant morbidity, 
mortality, and healthcare costs [1,2]. Airway inflammation 
is a key pathophysiologic feature of asthma, leading to 
airway obstruction, airway hyperresponsiveness (AHR), 
and even remodeling of the airway. Recent guidelines for 
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asthma management have therefore emphasized a need 
for the control of airway inflammation using inhaled 
corticosteroids (ICS) [3,4]. Chronic use of high-dose ICS, 
however, may result in serious side effects, including 
adrenal suppression and reduction in growth velocity, 
especially in children [5-7]. In addition, adequate ICS 
and other controller medications cannot achieve asthma 
control in some patients. Consequently, there is a pressing 
need for new alternative and/or complementary drugs 
with fewer side effects. 
Recently, a number of clinical and laboratory studies 
have investigated the anti-asthmatic effects of Chinese 
herbal products. Some of these herbal remedies have been 
shown to be effective and safe alternatives or complements 
to standard therapy for asthma and other allergic diseases 
[8]. Magnoliae flos (Chinese name, 辛夷, Xin-yi) has a 
long history of clinical use in Asian countries, and is used 
to treat ulceration of the nasal mucosa, allergic rhinitis, 
sinusitis, bronchial asthma, and other conditions [9]. 
NDC-052 (Han Kook Sin Yak Pharmaceutical Co. Ltd., 
Nonsan, Korea) is a purified extract of M. fargesii and 
was developed to enhance and control bioactive lignan 
content, including magnolin and epimagnolin A [10]. 
These bioactive lignans have been shown to inhibit various 
inflammatory mediators, such as platelet-activating factor 
(PAF), cytosolic phospholipase A2, hexosaminidase, 
lipoxygenase, the complement system, and production 
of leukotriene C4 [11,12]. A recent study demonstrated 
that epimagnolin decreased nitric oxide (NO) levels by 
modulating inducible nitric oxide synthase (iNOS) in 
human respiratory epithelial cells [13]. In addition, oral 
administration of 50 mg/kg NDC-052 for eight weeks 
reduced airway resistance in a guinea pig chronic asthma 
model (unpublished data). Taken together, these reports 
suggest that concentrated NDC-052 extract might have 
anti-inflammatory, as well as anti-asthmatic effects. 
Prior to the present study, the Korea Food & Drug 
Administration approved NDC-052 for clinical trials, 
and a phase II pilot study of NDC-052 in patients with 
persistent mild asthma found that a dose of 600 mg/day 
was effective and safe. We have evaluated the effects of 
NDC-052 as an add-on therapy to ICS in patients with 
persistent mild to moderate asthma symptoms.
MetHods
study design
This prospective, multi-center, non-comparative study 
was conducted in six university hospitals in Korea. After 
screening (visit 1), patients who voluntarily agreed to 
participate underwent a two-week ‘run-in’ period, during 
which they discontinued all asthma medications except 
ICS, which they had taken for at least four weeks. At the 
end of the run-in period (visit 2), we selected suitable 
subjects based on pulmonary function tests, symptom 
diaries, and laboratory data. At this point, ‘well-controlled’ 
asthma patients were excluded. ‘Well-controlled’ asthma 
was defined as an average of < 2 points on the asthma 
symptom score test, calculated as the sum of the following 
items (one point per item): no night-time awakening 
caused by asthma, no exacerbation of asthma symptoms, 
no usage of rescue medications, less than 20% peak 
expiratory flow rate (PEFR) variation, and no change in 
medications for the control of asthma symptoms, except 
for medications prescribed for one week. Patients who met 
the inclusion criteria were given NDC-052 (600 mg/day) 
for eight weeks. At subsequent four-week intervals (visits 
3 and 4), we evaluated their pulmonary function, clinical 
and laboratory parameters, and adverse reactions. 
This study was conducted in accordance with the 
Declaration of Helsinki and in compliance with Korean 
Good Clinical Practice and International Conference on 
Harmonization (ICH) Good Clinical Practice Guidelines. 
Each patient provided written informed consent before 
initiation of any study procedures. The study protocol and 
a copy of the informed consent document were reviewed 
and approved by the Institutional Review Board of each 
study center. 
subjects
We included study subjects aged 18-70 years with an at 
least three month history of asthma symptoms. Inclusion 
criteria at visit 1 included: 1) FEV1 ≥ 60% of the predicted 
value; 2) FEV1 increased ≥ 15% after the administration of 
either short-acting β2-agonist or oral corticosteroid (20-
40 mg/day) for 2-3 weeks; 3) FEV1 decreased ≥ 20% in 
response to the methacholine bronchial provocation test, 
with a PC20 value of less than 25 mg/mL; and 4) mild to 
moderate persistent asthma symptoms, based on the 2006 
Global Initiative for Asthma (GINA) diagnostic criteria. 86    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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Patients were excluded if they had any other pulmonary 
diseases, any severe co-morbidity, or had smoked more 
than 10 packs/yr and stopped smoking four weeks before 
screening. We also excluded women who were pregnant or 
breast-feeding.
Pulmonary function tests and clinical evaluations
FEV1 was measured at every visit and daily AM/PM 
PEFR was measured with a mini peak flow meter. The 
PEF was measured in the standing position immediately 
after waking in the morning and before going to bed in 
the evening. Patients were asked to measure PEF before 
taking medications, if possible, and were not asked to 
discontinue medications, including controllers, during 
the monitoring period. On each occasion, the best of at 
least three attempts was recorded. PEFR variability was 
defined by the following equation and was averaged over 
the period between each visit: (high PEF - low PEF) / 
mean PEF of the day × 100. We asked patients to assess 
symptom severity for two weeks before each visit, using 
a 100 mm visual analogue scale (VAS), ranging from no 
symptoms (0 mm) to the worst ever symptom (100 mm). 
This scale was used as a responsive outcome measurement 
and had been validated in previous clinical studies of 
patients with bronchial asthma [14,15]. Daytime asthma 
symptoms were scored as none (0), once for a short period 
of time (1), twice or more for short periods of time (2), all 
day without any major impact on normal daily activities 
(3), all day with an impact on normal daily activities (4), 
and symptoms so severe that it was impossible to conduct 
normal daily activities or work (5). Nocturnal asthma 
symptoms were scored as none (0), one awakening due to 
symptoms (1), two or more awakenings due to symptoms 
(2), and could not sleep at all because of symptoms (3). 
The frequency of nocturnal awakenings was defined as the 
frequency of days without night awakening due to asthma 
symptoms. The frequency of use for rescue medications 
was measured as the number of days that patients used 
these medications. 
safety evaluation
Safety data were obtained over eight weeks of treatment 
in all subjects. Causality of the event was assessed by 
the World Health Organization-Uppsala Monitoring 
Centre (WHO-UMC) criteria [16]. We graded severity as 
mild, moderate, or severe. Laboratory test results at each 
visit were compared with data obtained at the time of 
screening. 
statistical analysis
Results are shown as mean ± SD. The mean daytime 
and nocturnal asthma symptom scores were analyzed 
for the entire period between visits. All data on ‘0 week’ 
were obtained from a two-week ‘run-in’ period. Paired t tests 
were used to evaluate changes between baseline and 
after eight weeks of administration of the study drug. A p 
value < 0.05 was considered statistically significant. All 
statistical tests were performed using SAS version 8.0 (SAS 
Institute, Cary, NC, USA). For safety analysis, all abnormal 
events were placed into tables and their frequencies were 
calculated.
Results
subject characteristics
Of the 179 patients screened, 148 were enrolled and 
received NDC-052. These 148 patients included 56 
(37.84%) males and 92 (62.16%) females. Based on the 
GINA guidelines for severity, 113 subjects had mild 
persistent and 35 had moderate persistent asthma. Of 
the enrolled subjects, 101 (68.24%) were non-smokers, 11 
(7.43%) were current smokers, and 36 (24.32%) were ex-
smokers (Table 1).
effects of add-on ndC-052 on pulmonary function 
Treatment with add-on NDC-052 for eight weeks 
resulted in increases in mean AM and PM PEFR from 
baseline, and a decrease in mean daily PEFR variation. 
However, NDC-052 treatment did not result in a 
statistically significant improvement in FEV1 (Table 2).
effects of add-on ndC-052 on clinical parameters
We found that eight weeks of add-on NDC-25 resulted in 
significant improvements in both daytime and nocturnal 
symptom scores. In addition, add-on treatment reduced 
100 mm VAS scores, as well as reduced the frequency of 
nighttime awakening and use of rescue medication after 
eight weeks (Table 3).
safety evaluation
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patients. Analysis of the causality between adverse events 
and NDC-052 showed that only one event (0.97%) was 
‘probable,’ 28 events (27.18%) were ‘possible,’ and 74 
(71.84%) were ‘unlikely.’ The 29 adverse events classified 
as ‘probably’ and ‘possibly’ associated with NDC-052 
are shown in Table 4. Although five events (4.85%) were 
classified as severe, none were correlated with NDC-052. 
Laboratory findings at screening and eight weeks showed 
no significantly abnormal findings.
 
dIsCussIon
We have shown here that the addition of NDC-052, 
an extract of an herbal remedy, to ICS may play a role 
in improving asthma control in patients with mild to 
moderate asthma. NDC-052 improved the results of 
pulmonary function tests, such as AM and PM PEFR and 
PEFR variation, as well as clinical parameters, including 
asthma symptom VAS, daytime and nocturnal asthma 
symptoms, the frequency of night-time awakening, and 
the frequency of β2-agonist use. In addition, NDC-052 
was well tolerated and no severe adverse reactions were 
observed. 
Traditional Chinese medicine (TCM) is one of the oldest 
types of medical practice in the world, and has played an 
table 3. Changes in clinical measurements
Variables 0 wk 4 wks 8 wk ∆ 8-0 wk p value
a
Daytime symptom score 1.5 ± 1.1 1.2 ± 1.1 1.0 ± 1.1 -0.5 ± 1.1 < 0.0001
Nocturnal symptom score 0.6 ± 0.6 0.4 ± 0.6 0.5 ± 0.7 -0.1 ± 0.6    0.0343
100 mm VAS, mm 42.4 ± 19.7 33.9 ± 19.3 31.6 ± 22.1 -10.6 ± 19.7 < 0.0001
Frequency of night-time awakening 3.8 ± 2.8 4.6 ± 2.9 4.5 ± 3.0  0.7 ± 2.9    0.0070
β2-agonist use   7.5 ± 12.1   5.3 ± 10.9   4.8 ± 11.7   -2.4 ± 10.4    0.0102
∆, difference between 0 and 8 wk; VAS, visual analogue scale.
apaired t tests on the difference between 0 and 8 wk.
table 1. Baseline demographic and clinical 
characteristics of patients
Characteristics No. (%)
Male/Female 56 (37.84)/92 (62.16)
Age, yr 45.30 ± 13.93
History of atopic disease
Yes 23 (15.54)
No 125 (84.46)
Asthma duration 60.85 ± 85.89
< 6 mon 21 (14.19)
6 mon-1 yr 26 (17.57)
1-2 yr 20 (13.51)
2-3 yr 12 (8.11)
3-5 yr 21 (14.19)
5-10 yr 23 (15.54)
> 10 yr 25 (16.89)
Smoking status
Non-smoker 101 (68.24)
Ex-smoker 36 (24.32)
Current smoker 11 (7.43)
pack year 6.25 ± 2.81
Severity
a
Mild persistent
Moderate persistent
113 (76.35)
  35 (23.65)
aAccording to Global Initiative for Asthma (GINA) 2006 
guidelines.
table 2. Changes in pulmonary function during treatment
Variables 0 wk 4 wk 8 wk ∆ 8-0 wk p value
a
FEV1, mL 2,586.7 ± 845.5 2,594.7 ± 856.5 2,582.45 ± 855.1      -5.6 ± 268.9 0.8140
AM PEFR, mL     364.8 ± 106.6    377.0 ± 113.0     378.9 ± 114.1   11.4 ± 42.0 0.0026
PM PEFR, mL     373.3 ± 105.0    381.6 ± 110.2     385.2 ± 111.8   10.6 ± 35.4 0.0009
PEFR variation, %     7.7 ± 8.1    6.5 ± 5.6     5.9 ± 7.8  -1.3 ± 7.4 0.0427
∆, difference between 0 and 8 wk; FEV1, forced expiratory volume in one second; PEFR, peak expiratory flow rate.
apaired t tests on the difference between 0 and 8 wk.88    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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important role for centuries in preventing and treating 
diseases in China and other Asian countries. Recently, 
TCM has been tested for the treatment of allergic diseases, 
including asthma, allergic rhinitis, and food allergy. The 
anti-asthma herbal medicines being evaluated include 
MSSM-002, modified Mai Men Dong Tang, Ding Chuan 
Tang, and STA-1, with clinical trials suggesting that 
these TCM remedies are efficacious and safe alternatives 
or complements to standard Western asthma therapy 
[8,17,18].
In this context, NDC-052 extracted from M. flos using 
ethanol, is a well-known natural herbal remedy in East 
Asian countries, including Korea, China, and Japan. 
M. flos refers to the flower buds of M. denudata and 
other plants belonging to the same genus, including M. 
fargesii (also known as M. biondii), M. denudata, M. 
liliflora, M. salicifolia, and M. kobus. Extraction yields 
many compounds, including oils, lignan compounds, 
and sesquiterpenes [10,19,20]. Some of the compounds 
extracted from both M. fargesii and M. denudata were 
shown to be calcium antagonists, inhibiting the activity of 
PAF and serum complement, and reducing tumor necrosis 
factor-alpha (TNF-alpha) production [11,12,20-23]. Using 
an anaphylaxis model in mice, M. flos was shown to inhibit 
immediate-type allergic reactions by inhibiting mast cell 
degranulation, both in vivo and in vitro [24]. Moreover, 
epimagnolin, a major lignin of NDC-052, was shown to 
inhibit the expression of iNOS and the production of NO 
via extracellular signal-regulated kinase (ERK) pathway 
in cytokine-stimulated human respiratory epithelial cells 
[13]. Thus, NDC-052 may have both anti-inflammatory 
and antioxidant effects, and the pathway by which NDC-
052 reduces inflammation may differ from that of steroids. 
Therefore, NDC-052 may provide additional benefits to 
asthma patients using ICS. 
We found that treatment with add-on NDC-052 did not 
noticeably increase FEV1. Most of our subjects, however, 
had mild persistent asthma, with FEV1 > 80% of the 
predicted value. Nevertheless, NDC-052 improved AM 
and PM PEFR and other clinical indicators of asthma 
control, such as the need for β-agonist relief therapy and 
both day and night asthma symptom scores. In recent 
guidelines, these clinical outcomes were regarded as 
important characteristics for evaluating asthma control. 
Therefore, our data indicate that patients with close-to-
normal FEV1 levels may be symptomatic and require 
additional control of asthma symptoms. In addition, our 
results were similar to those of previous studies showing 
that addition of ICS to leukotriene receptor antagonists, 
currently used as alternatives to ICS in patients with 
mild persistent asthma, improved various measurements 
of asthma control, despite failing to cause a significant 
improvement in FEV1 [25,26]. Pharmacologically, NDC-
052 has anti-inflammatory, rather than bronchodilating, 
effects. Therefore, NDC-052 may not directly affect FEV1 
level. We did not measure inflammatory markers in these 
patients, suggesting the need for additional clinical studies 
involving measurements of inflammatory markers, such 
as induced sputum analysis or exhaled NO, to determine 
the mechanisms by which NDC-052 affects airway 
inflammation. Further clinical trials are necessary to 
determine if the addition of NDC-052 to ICS is effective in 
patients with more severe or refractory asthma, or if it can 
decrease the frequency of asthma exacerbation. 
ICS has been shown to improve both asthma-related 
symptoms and pulmonary function in many patients, 
although a subset of patients required additional 
medications to achieve asthma control. Updated GINA 
guidelines suggest that symptoms can be improved by: 
1) increasing the dose of ICS, 2) adding inhaled long-
acting β2-agonists (LABA), or 3) adding other controller 
table 4. Adverse events
Variables No. (%)
Dyspnea 1 (0.97)
Epigastric soreness 4 (3.88)
Indigestion 7 (6.80)
Nausea 4 (3.88)
Constipation 2 (1.94)
Vomiting 1 (0.97)
Abdominal pain 1 (0.97)
Dysphagia 1 (0.97)
paresthesia 1 (0.97)
Migraine 1 (0.97)
Facial swelling 1 (0.97)
pruritus 1 (0.97)
Urticaria 1 (0.97)
Rash 1 (0.97)
Skin exfoliation 1 (0.97)
Myalgia 1 (0.97)
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medications, such as leukotriene modifiers and sustained-
release theophylline. Since ICS has a plateau effect, such 
that increased doses are not matched by further increases 
in efficacy [27,28], the updated GINA recommends the 
addition of a controller, preferably LABA, rather than 
increasing the dose of ICS. LABA, however, does not have 
anti-inflammatory effects, raising concerns that it may 
enhance airway remodeling [29]. In addition, inhaled 
agents may fail to reach the small airways, i.e., the site 
of inflammation in asthma. Theophylline, a currently 
available oral controller, has a narrow therapeutic window 
and many side effects, limiting its utility as an add-on 
therapy in asthmatics suboptimally controlled with ICS. 
These findings indicate the need for novel alternative 
agents that can improve airway inflammation and asthma 
symptoms in patients who cannot be controlled by ICS 
alone. 
However, the design of this study imposes some 
limitations on the interpretation of the results. First, the 
absence of a placebo group precluded assessment of any 
placebo effect on asthma symptoms; thus, improvements 
in outcome measures may have been influenced by the 
expectation of a benefit from treatment. Secondly, the 
increased compliance to ICS may have affected the results. 
However, we strongly suggested that participants use their 
ICS regularly during the whole study period, including 
run-in periods, and enrolled symptomatic patients 
despite regular ICS usage. Finally, eight weeks was a 
relatively short period to evaluate the long-term effects 
of therapeutic drugs on asthma control. Further clinical 
trials are necessary to address these issues. 
In conclusion, we have shown that add-on NDC-052 was 
well tolerated and shows potential for improving asthma 
control in patients with persistent symptoms treated with 
ICS. Further clinical trials are needed to test the efficacy 
and safety of NDC-052 in patients with severe and/or 
refractory asthma.
Conflict of interest
This study was financially supported by Han Kook Sin 
Yak Pharmaceutical Co. Ltd., Nonsan, Korea.
RefeRenCes
1.  Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir 
J 1996;9:636-642.
2.  Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for 
Asthma (GINA) Program. The global burden of asthma: execu-
tive summary of the GINA Dissemination Committee report. 
Allergy 2004;59:469-478.
3.  National Institutes of Health, National Heart, Lung, and Blood 
Institute. National asthma education and prevention program: 
global strategy for asthma management and prevention. Global 
Initiative for Asthma report [Internet]. National Institutes of 
Health, National Heart, Lung, and Blood Institute, 2009 [cited 
2011 Dec 20]. Available from http://www.ginasthma.org.
4.  Jang AS. Inhaled steroids in asthma therapy: an update. Ko-
rean J Med 2011;80:129-134.
5.  Visser MJ, van der Veer E, Postma DS, et al. Side-effects of fluti-
casone in asthmatic children: no effects after dose reduction. 
Eur Respir J 2004;24:420-425.
6.  Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S. De-
creased morning serum cortisol levels in children with 
asthma treated with inhaled fluticasone propionate. Pediatrics 
2002;109:217-221.
7.  Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Sup-
pression of hypothalamic-pituitary-adrenal axis activity with 
inhaled flunisolide and fluticasone propionate in adult asthma 
patients. Ann Allergy Asthma Immunol 2001;87:379-385.
8.  Li XM. Traditional Chinese herbal remedies for asthma and 
food allergy. J Allergy Clin Immunol 2007;120:25-31.
9.  Shen Y, Li CG, Zhou SF, Pang EC, Story DF, Xue CC. Chemistry 
and bioactivity of Flos Magnoliae, a Chinese herb for rhinitis 
and sinusitis. Curr Med Chem 2008;15:1616-1627.
10.  Chen CC, Huang YL, Chen HT, Chen YP, Hsu HY. On the Ca++-
antagonistic principles of the flower buds of Magnolia fargesii. 
Planta Med 1988;54:438-440.
11.  Jung KY, Kim DS, Oh SR, et al. Magnone A and B, novel anti-
PAF tetrahydrofuran lignans from the flower buds of Magnolia 
fargesii. J Nat Prod 1998;61:808-811.
12.  Ahn KS, Jung KY, Kim JH, Oh SR, Lee HK. Inhibitory activity 
of lignin components from the flower buds of Magnoliae fargesii 
on the expression of cell adhesion molecules. Biol Pharm Bull 
2001;24:1085-1087.
13.  Baek JA, Lee YD, Lee CB, et al. Extracts of Magnoliae flos in-
hibit inducible nitric oxide synthase via ERK in human respira-
tory epithelial cells. Nitric Oxide 2009;20:122-128.
14.  Brightling CE, Monterio W, Green RH, et al. Induced sputum 
and other outcome measures in chronic obstructive pulmonary 
disease: safety and repeatability. Respir Med 2001;95:999-
1002.
15.  Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-
eosinophilic corticosteroid unresponsive asthma. Lancet 
1999;353:2213-2214.
16.  The Uppsala Monitoring Centre. The use of the WHO-UMC 90    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
http://dx.doi.org/10.3904/kjim.2012.27.1.84 http://www.kjim.or.kr
system for standardized case causality assessment [Internet]. 
Uppsala: The Uppsala Monitoring Centre, 2010 [cited 2011 Dec 
20]. Available from: http://who-umc.org/Graphics/24734.pdf.
17.  Bielory L, Lupoli K. Herbal interventions in asthma and allergy. 
J Asthma 1999;36:1-65.
18.  Li XM, Zhang TF, Sampson H, et al. The potential use of Chi-
nese herbal medicines in treating allergic asthma. Ann Allergy 
Asthma Immunol 2004;93(2 Suppl 1):S35-S44.
19.  Iida T, Nakano M, Ito K. Hydroperoxysesquiterpene and lignan 
constituents of Magnolia kobus. Phytochemistry 1982;21:673-
675.
20.  Pan JX, Hensens OD, Zink DL, Chang MN, Hwang SB. Lignans 
with platelet activating factor antagonist activity from Magnolia 
biondii. Phytochemistry 1987;26:1377-1379.
21.  Chae SH, Kim PS, Cho JY, et al. Isolation and identification of 
inhibitory compounds on TNF-alpha production from Magno-
lia fargesii. Arch Pharm Res 1998;21:67-69.
22.  Huang YL, Chen CC, Chen YP, Hsu HY, Kuo YH. (-)-Fargesol, a 
new lignan from the flowers buds of Magnolia fargesii. Planta 
Med 1990;56:237-238.
23.  Jung KY, Oh SR, Park SH, et al. Anti-complement activity of 
tiliroside from the flower buds of Magnolia fargesii. Biol Pharm 
Bull 1998;21:1077-1078.
24.  Kim HM, Yi JM, Lim KS. Magnoliae flos inhibits mast cell-
dependent immediate-type allergic reactions. Pharmacol Res 
1999;39:107-111.
25.  Price DB, Hernandez D, Magyar P, et al. Randomised controlled 
trial of montelukast plus inhaled budesonide versus double 
dose inhaled budesonide in adult patients with asthma. Thorax 
2003;58:211-216.
26.  Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast 
added to inhaled budesonide on control of mild to moderate 
asthma. Thorax 2003;58:204-210.
27.  Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of in-
haled corticosteroids: new developments. Am J Respir Crit Care 
Med 1998;157(3 Pt 2):S1-S53.
28.  Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley 
R. Dose-response relation of inhaled fluticasone propionate 
in adolescents and adults with asthma: meta-analysis. BMJ 
2001;323:253-256.
29.  Vanacker NJ, Palmans E, Pauwels RA, Kips JC. Effect of com-
bining salmeterol and fluticasone on the progression of airway 
remodeling. Am J Respir Crit Care Med 2002;166:1128-1134.